Cargando…

Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial

OBJECTIVE: This study (NCT00969436) compared the immunogenicity and safety of measles-mumps-rubella (MMR) followed by MMR+varicella (V) vaccines to (1) 2 doses of combined MMRV and (2) MMR followed by MMRV, in Indian children. DESIGN: Phase III, open, randomised, non-inferiority study. SETTING: 6 te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lalwani, Sanjay, Chatterjee, Sukanta, Balasubramanian, Sundaram, Bavdekar, Ashish, Mehta, Shailesh, Datta, Sanjoy, Povey, Michael, Henry, Ouzama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Paediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567664/ https://www.ncbi.nlm.nih.gov/pubmed/26362659 http://dx.doi.org/10.1136/bmjopen-2014-007202

Ejemplares similares

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children
por: Cha, Sung-Ho, et al.
Publicado: (2014)

Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: A phase II, randomized, double-blind trial
por: Huang, Li-Min, et al.
Publicado: (2013)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study
por: Abu-Elyazeed, Remon, et al.
Publicado: (2018)

Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety
por: Ma, Shu-Juan, et al.
Publicado: (2015)

Inadequate Measles, Mumps, Rubella, and Varicella Immunity Among Employees
por: Ezeji-Okoye, Stephen, et al.
Publicado: (2021)

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial
por: Bavdekar, Ashish, et al.
Publicado: (2018)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study
por: dos Santos, Eliane Matos, et al.
Publicado: (2019)

Adverse events following measles-mumps-rubella-varicella vaccine: an independent perspective on Italian pharmacovigilance data
por: Bellavite, Paolo, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines
por: Bonanni, Paolo, et al.
Publicado: (2019)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age
por: Haas, Hervé, et al.
Publicado: (2019)

Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes
por: Conway, Justin J., et al.
Publicado: (2018)

Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis
por: Schenk, Julie, et al.
Publicado: (2021)

Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination
por: Hussein, Siti Zuhaida, et al.
Publicado: (2022)

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin
por: Berry, Andrea A., et al.
Publicado: (2017)

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
por: Hanson, Kayla E., et al.
Publicado: (2023)

Seroprevalence of Measles, Mumps, Rubella and Varicella Antibodies in the United States Population, 2009–2010
por: Lebo, Emmaculate J., et al.
Publicado: (2015)

Partial third nerve palsy after Measles Mumps Rubella vaccination
por: Manzotti, Francesca, et al.
Publicado: (2010)

Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart
por: Zamanian, Abbas, et al.
Publicado: (2014)

Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm
por: Jama, Asha, et al.
Publicado: (2018)

Reply to Özdemir, “Measles-Mumps-Rubella Vaccine and COVID-19 Relationship”
por: Fidel, Paul L., et al.
Publicado: (2020)

Measles-mumps-and-rubella-virus-vaccine: Aseptic meningitis: case report
Publicado: (2021)

Measles mumps and rubella virus vaccine: Various toxicities: case report
Publicado: (2022)

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021)

Buschke–Lowenstein tumor treated with intralesional measles, mumps, and rubella vaccine
por: Deshmukh, Ashish, et al.
Publicado: (2022)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness
por: Ödemiş, İlker, et al.
Publicado: (2019)

Lower Transplacental Antibody Transport for Measles, Mumps, Rubella and Varicella Zoster in Very Preterm Infants
por: van den Berg, Jolice P., et al.
Publicado: (2014)

Seroprevalence of measles, mumps, rubella, varicella–zoster and hepatitis A–C in Emirati medical students
por: Sheek-Hussein, Mohamud, et al.
Publicado: (2012)

P280: Seroprevalence of measles, rubella, mumps, and varicella among health care workers in Japan
por: Watanabe, T, et al.
Publicado: (2013)

Seroprevalence of measles, mumps, rubella, and varicella-zoster antibodies in new female nurses in the Republic of Korea
por: Yoo, Yeongjae, et al.
Publicado: (2021)

Mumps Antibody Response in Young Adults After a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Measles–mumps–rubella vaccination and respiratory syncytial virus-associated hospital contact
por: Sørup, Signe, et al.
Publicado: (2015)

Comparison of Intralesional Measles, Mumps, Rubella Vaccine and Needling in the Treatment of Recurrent Warts
por: Kolte, Surabhi R., et al.
Publicado: (2020)

Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management
por: Magistà, Stefania, et al.
Publicado: (2020)

1209. Seroprevalence of Measles, Mumps, and Rubella in Korean Healthcare Workers and Strategy for Vaccination
por: Ju Choo, Eun, et al.
Publicado: (2019)

Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma
por: Khalid, Zumama, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nbuqkjjedvgmp9lnad06e13kp3